Taken together, we proposed that metformin could inhibit NF-κB p65 signaling by activating AMPK and inhibiting downstream ERK/ NF-κB to suppress lung cancer progression (Figure 5H). The gene discussed is NFKB1; the disease is lung carcinoma.